Dyrk1b Promotes Hepatic Lipogenesis by Bypassing Canonical Insulin Signaling and Directly Activating mTORC2 in Mice

The authors provided new insights into the mechanisms that underlied Dyrk1b-induced hepatic lipogenesis and hepatic insulin resistance and identified Dyrk1b as a therapeutic target for non-alcoholic liver steatohepatitis and insulin resistance in the liver.